CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company developing bladder-sparing therapeutics for bladder cancer, has announced upcoming presentations at two major investor conferences. The company's leadership team, including Chairman & CEO Arthur Kuan and President & COO Ambaw Bellete, will participate in fireside chats at:
- The Cantor Global Healthcare Conference on September 5, 2025, at 10:20am ET
- The Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45am ET
Both presentations will be accessible via webcast on the company's investor relations website and will remain archived for approximately 90 days.
CG Oncology (NASDAQ: CGON), azienda biofarmaceutica in fase clinica avanzata specializzata in terapie che preservano la vescica per il cancro alla vescica, ha annunciato la partecipazione a due importanti conferenze per investitori. Il management, rappresentato da Arthur Kuan, Chairman & CEO, e da Ambaw Bellete, President & COO, prenderà parte a discussioni informali (fireside chats) nelle seguenti date:
- Cantor Global Healthcare Conference: 5 settembre 2025, ore 10:20 ET
- Morgan Stanley 23rd Annual Global Healthcare Conference: 9 settembre 2025, ore 7:45 ET
Entrambe le presentazioni saranno trasmesse via webcast sul sito investor relations della società e resteranno archiviate per circa 90 giorni.
CG Oncology (NASDAQ: CGON), compañía biofarmacéutica en etapa clínica avanzada que desarrolla terapias conservadoras de vejiga para el cáncer vesical, ha anunciado presentaciones en dos importantes conferencias para inversores. El equipo directivo, encabezado por Arthur Kuan, Chairman & CEO, y Ambaw Bellete, President & COO, participará en charlas tipo "fireside" en:
- Cantor Global Healthcare Conference: 5 de septiembre de 2025, 10:20 a.m. ET
- Morgan Stanley 23rd Annual Global Healthcare Conference: 9 de septiembre de 2025, 7:45 a.m. ET
Ambas presentaciones se podrán ver en webcast en la web de relaciones con inversores de la compañía y permanecerán archivadas durante aproximadamente 90 días.
CG Oncology (NASDAQ: CGON), 방광암 환자의 방광 보존 치료제를 개발하는 후기 임상 단계의 바이오제약사로서, 주요 투자자 컨퍼런스 두 곳에서 발표를 진행한다고 밝혔습니다. 대표 경영진인 의장 겸 CEO 아서 콴(Arthur Kuan)과 사장 겸 COO 암바우 벨레테(Ambaw Bellete)가 다음 행사에서 파이어사이드 채팅에 참여합니다:
- Cantor Global Healthcare Conference: 2025년 9월 5일, 동부시간 오전 10:20
- Morgan Stanley 23rd Annual Global Healthcare Conference: 2025년 9월 9일, 동부시간 오전 7:45
두 발표 모두 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있으며, 약 90일간 아카이브로 제공됩니다.
CG Oncology (NASDAQ: CGON), société biopharmaceutique en phase clinique avancée développant des traitements préservant la vessie pour le cancer de la vessie, a annoncé des présentations lors de deux grandes conférences pour investisseurs. L'équipe dirigeante, composée de Arthur Kuan, Chairman & CEO, et de Ambaw Bellete, President & COO, participera à des "fireside chats" aux dates suivantes :
- Cantor Global Healthcare Conference : 5 septembre 2025 à 10h20 ET
- Morgan Stanley 23rd Annual Global Healthcare Conference : 9 septembre 2025 à 7h45 ET
Les deux présentations seront accessibles en webcast sur le site relations investisseurs de la société et resteront archivées pendant environ 90 jours.
CG Oncology (NASDAQ: CGON), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das blasenerhaltende Therapien für Blasenkrebs entwickelt, hat angekündigt, auf zwei bedeutenden Investorenkonferenzen präsent zu sein. Die Geschäftsführung, vertreten durch Chairman & CEO Arthur Kuan und President & COO Ambaw Bellete, wird an folgenden Fireside-Chats teilnehmen:
- Cantor Global Healthcare Conference am 5. September 2025 um 10:20 Uhr ET
- Morgan Stanley 23rd Annual Global Healthcare Conference am 9. September 2025 um 7:45 Uhr ET
Beide Präsentationen sind per Webcast über die Investor-Relations-Website des Unternehmens zugänglich und werden für etwa 90 Tage archiviert.
- None.
- None.
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, are scheduled to participate in fireside chat presentations at the following investor conferences:
- Cantor Global Healthcare Conference – presenting Friday, September 5, 2025, at 10:20am ET in New York, NY
- Morgan Stanley 23rd Annual Global Healthcare Conference – presenting Tuesday, September 9, 2025, at 7:45am ET in New York, NY
Interested parties may access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available shortly after the conclusion of the live presentation and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com
FAQ
When is CG Oncology (CGON) presenting at the Cantor Global Healthcare Conference 2025?
When is CG Oncology's presentation at the Morgan Stanley Healthcare Conference 2025?
How can investors access CG Oncology's (CGON) conference presentations?
What type of company is CG Oncology (CGON)?
